Several thousand different types of rare diseases and disorders exist, with more being discovered each day. In recent years, the interest for rare diseases has grown throughout the entire medical community. However, the road to an approved orphan drug is a long and costly one with many challenges on the way including regulatory, financial, sustainability and pricing and reimbursement issues.
Returning for its 4th year and following on from the major success of previous events, SMi is proud to announce that registration is now live for the 4th Annual Orphan Drugs and Rare Diseases Conference taking place on 19th–20th October 2015 in London, UK.
Through a series of interactive presentations and panel discussions, attendees will learn how payers, pharmaceutical, biotech, patient organizations and academia are structuring to participate in and leverage the growing orphan drugs and rare diseases market.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.